TransCode Therapeutics Inc. (NASDAQ: RNAZ) stock declined by 3% at the last close whereas the RNAZ stock price gains by 5.79% in the pre-market trading session. TransCode is a new RNA oncology business founded on the premise that cancer may be vanquished via the clever design and distribution of RNA therapies.
RNAZ stock’ Recent Past Development
TransCode Therapeutics has announced the appointment of Zdravka Medarova, Ph.D. as Chief Technology Officer, started October 1, 2021.
Dr. Medarova is a scientific co-founder of TransCode and has been on the advisory panel since the company’s inception in January 2016. Dr. Medarova comes to TransCode from Harvard Medical School and MGH, where she was an Associate Professor of Radiology at Harvard Medical School and an Assistant in Neuroimaging at MGH’s Athinoula A. Martinos Center for Biomedical Imaging. Dr. Medarova’s work in the field of RNA oncology was ground-breaking. She discussed the creation and deployment of iron oxide nanoparticles as imaging-capable carriers of siRNA to tumors for the first time alongside her MGH colleagues.
Michael Dudley, CEO of TransCode commented,
They are thrilled to welcome Zdravka to the TransCode team as a full-time employee. Her significant experience in creating nanotechnology and imaging techniques to better understand cancer genesis and development has long been beneficial to them. Her ties with Harvard Medical School and Massachusetts General Hospital also helped them with their preclinical research. As they work to validate their TTX technology as a realistic way to implement the potential of RNA therapeutics in cancer therapy, Zdravka’s leadership will be crucial.
Dr. Medarova stated,
In addition to assisting the firm as a researcher and advisor, as one of TransCode’s scientific co-founders, she has had extensive exposure to the company’s TTX delivery technology and lead candidate, TTX-MC138. Based on the observations, she believes TransCode’s method has the potential to ultimately overcome the chronic problem of RNA delivery in cancer, with enormous patient benefit. She is excited to join TransCode at this critical juncture in its development.
